Back to News
Market Impact: 0.35
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
Source: marketbeat.com
Healthcare & BiotechTechnology & InnovationCompany Fundamentals
Regeneron and Sanofi expanded their collaboration to develop next-generation treatments for type 2 inflammatory diseases. The alliance builds on the success of blockbuster therapy DUPIXENT, potentially extending both companies' immunology franchises and long-term pipeline opportunities.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
REGN0.65
SNY0.60
More News
- Jefferies raises Regeneron stock price target to $930 on partnership
- Sanofi to pay Regeneron up to $8 billion to add new antibodies under Dupixent partnership
- Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
- Communiqué de presse : Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée
- Why the media’s whisper campaign about a Goldman Sachs change at the top is misleading gossip, at best
- Nvidia Faces Questions Over China AI Chip Smuggling Cases